(PharmaNewsWire.Com, October 19, 2017 ) The Global Plasma Fractionation Market was worth USD 19.4 billion in 2016 and is projected to be growing at a CAGR of 7.2%, to touch USD 27.46 billion by 2021. Blood fractionation is the process of fractionating whole blood or segregating it into its constituent parts. Whole blood consists of red cells, white cells, and platelets, suspended in plasma, which constitutes about 55% of blood by volume.
Plasma is the liquid portion of blood. It not only consists of red cells, white cells and platelets suspended in it, but also contains thousands of distinct proteins and other substances like electrolytes, minerals, hormones, etc., which are necessary for the normal function of the human body. Plasma helps in maintaining blood pressure and body temperature regulation.
The growth of the Global Plasma Fractionation Market is mainly driven by factors such as increasing incidence of immune and bleeding disorders, growing incidence of Alpha-1 Antitrypsin deficiency and the rising use of immunoglobulins, which are basically antibodies. Further, growing aging population with related blood related ailments is set to further drive market growth. However, adverse reactions associated with the use of plasma fractionation and transfer, high costs of plasma products and unfavourable reimbursement policies are the major constraints of market growth.
The Global Plasma Fractionation Market is segmented on the basis of Product, Application, End User and Geography. Based on Product, the market is divided into Albumin, Immunoglobulin, Factor VIII, and Protease Inhibitors. Based on Application, the Plasma Fractionation Market is segmented into Neurology, Haematology, Rheumatology, Pulmonology, and Immunology. Based on the End User, it is categorized into Hospital and Clinical Laboratories.
Global Plasma Fractionation Market Geographical Analysis North America Europe Asia-Pacific Latin America Middle East & Africa
As of 2016, North America leads the market, with the U.S. accounting for a major share. North Americas lead is justified by the presence of high number of registered haemophilic patients and increasing use of immunoglobulins in neurologic disorders. Europe comes in second in terms of market share owing to the rising awareness about blood related disorders and the swift availability of treatment in terms of plasma fractionation. However, Asia-Pacific is estimated to grow at the highest CAGR during the forecast period majorly because of the presence of larger elderly population numbers leading to higher incidence of blood disorders.
Global Plasma Fractionation Market Leaders' Analysis Baxalta Incorporated CSL Ltd. Grifols S.A Octapharma AG Kedrion S.p.A Bio Products Laboratory Sanquin China Biologic Products, Inc. Biotest AG Laboratoire Franηais du Fractionnement et des Biotechnologies
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
